A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
about
Current ebola vaccinesEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentEbolavirus vaccines for humans and apesClinical development of Ebola vaccinesEbola virus vaccines: an overview of current approachesPreparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught UsZika virus protection by a single low-dose nucleoside-modified mRNA vaccinationA review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola VirusPrevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicineSafety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialRecombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeFunctional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection.Ebolavirus in West Africa, and the use of experimental therapies or vaccines.Filovirus vaccines.The UCSC Ebola Genome PortalClinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaquesSafety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Potential vaccines and post-exposure treatments for filovirus infections.Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.Novel vaccine strategies against emerging viruses.Oral Modeling of an Adenovirus-Based Quadrivalent Influenza Vaccine in Ferrets and Mice.Vaccines for viral hemorrhagic fevers--progress and shortcomingsOncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccinesBoHV-4-based vector delivering Ebola virus surface glycoprotein.Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes.Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.
P2860
Q21534720-BA7A1B08-A790-400F-ADD7-8A90B4B8E47CQ24597625-10A0A4B7-0253-447B-AB63-0E3366DDE2A9Q24631696-E0D79FA6-09F1-4061-A208-7207397E036EQ26775792-B956F7AE-A552-48A5-A5FF-547302D6F078Q26999232-46505290-8B46-4B94-90EF-EACCB9212158Q28397866-1590D06E-3103-4E0B-9BDC-C3CD7263DC29Q28656365-3602A1F2-85C6-4D2C-B1B9-6D3BFDF2AF33Q29994671-7D74E36A-5B49-4D2A-B5E2-9E9A0D35582BQ30235073-E8BF8112-DBCE-449C-81BC-24A06324BCFFQ30405726-39BE66B4-A1D0-421B-AFF6-20D3EF12A56CQ34170122-0706B4D9-8276-47F1-B72E-7E19CEAEF3D4Q34263835-51108060-C7C0-4BD9-BCA0-4AADA2653384Q34437167-97FEEB17-ABF3-4471-B73F-39021F23E4A7Q34463780-EEF4F4F4-6A98-4B70-B043-559A61BE9257Q34971349-3AAF4FFB-6FFE-458C-917E-0F4754C69CB8Q35048254-E7CF10CC-82AD-4CF9-A061-D46C220656B1Q35055198-292DD3A3-2D21-464B-BF44-B5B1BF5B205FQ35076828-06E6C4EA-DB28-4578-9BEE-13C54BE79496Q35193052-951A8718-331E-4C57-9980-424CE18B006DQ35305323-92689A9D-ACDC-4257-B46C-EED01423B655Q35558539-9294855D-6204-49AE-B9D7-4F1F899A8D21Q35562017-DC1ACF0E-B6C4-44C7-AE24-92CA5F7966E4Q35741984-CDECE0B5-2D38-46A6-8E64-29164AEC25DEQ35741989-EC5F0E02-D4E8-4ADA-AC95-846376B71F36Q36157283-1950DFAC-88A0-4001-B01F-728BB86D0E8EQ36192765-5BC6958B-95BF-4289-84D6-245075E41FC4Q36404178-8935DA4B-770A-4F07-8015-C0753CFB96D7Q36463070-CCC67B77-0DDE-4239-A0AC-26C9B2C33B00Q36555158-540CA2B6-65D3-4F51-A7C2-1A5A968D933DQ36768279-D6629A63-16D2-43A7-9ACA-220B09BAD230Q36816140-3F248D37-E976-456F-B283-923296083BD0Q37056528-814ABD87-024F-4DB9-B387-725DA0536B42Q37096221-72AADF74-2B5C-428D-BC15-A2C4EA48529BQ37196054-61FE0B81-46B3-48CE-BA60-0B4074176C3FQ37436625-E93FDDBE-2850-4DDD-98AC-D7A8977EA894Q37545021-FFB058E7-862D-4053-8655-1A306A0E067DQ37713766-21252500-69D7-4C9D-9605-D7057E65592CQ37718956-27FA5A06-234A-44C0-B2CB-2B6BEC365C9BQ37932525-B4265FA7-B24C-4CA6-AA1E-F17494D38EC8Q37976671-7BC67514-CCCE-4433-9FB4-4751E9B23CBE
P2860
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A replication defective recomb ...... immunogenic in healthy adults.
@en
type
label
A replication defective recomb ...... immunogenic in healthy adults.
@en
prefLabel
A replication defective recomb ...... immunogenic in healthy adults.
@en
P2093
P1433
P1476
A replication defective recomb ...... immunogenic in healthy adults.
@en
P2093
B S Graham
C A Andrews
G Yamshchikov
J E Ledgerwood
J Goudsmit
J R Mascola
P304
P356
10.1016/J.VACCINE.2010.10.037
P407
P577
2010-10-27T00:00:00Z